top of page

Rafarma Pharmaceuticals met with the Kazakhstan chief specialist in nuclear medicine

Rafarma Pharmaceuticals (OTC: RAFA) representatives held an online meeting with Aigul Saduakasova, a leading radioisotope diagnostics doctor in Kazakhstan. At the meeting, the parties discussed the prospects for the development of several projects:

  • Registration of new radiopharmaceuticals, primarily developed by Rafarma Pharmaceuticals

  • Registration of products for Radisilvectomy and Radioembolization


Aigul is a member of the Radiological Society of Kazakhstan, the European Society of Radiology, and the European Association of Nuclear Medicine. Having impressive experience, Aigul underwent specializations at BIONT (Slovak Republic), Spedali Civili Hospital (Italy), ROTOBO (Japan), Saint Antonius Hospital (Netherlands), and Malaysian Nuclear Agency (Malaysia).


Rapharma Pharmaceuticals thanks Aigul Saduakasova for a productive meeting and looks forward to continued cooperation.


ABOUT RAFARMA PHARMACEUTICALS

Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging, and many other fields at the moment.


For more information, please visit https://www.noyarp.com


FORWARD-LOOKING STATEMENT:

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

CONTACTS:

RAFARMA PHARMACEUTICALS

(307) 429-2029


Source: Rafarma Pharmaceuticals, Inc.



Comments


bottom of page